Form 8-K MANNKIND CORP For: Nov 09
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2015
MannKind Corporation
(Exact name of registrant as specified in its charter)
| Delaware | 000-50865 | 13-3607736 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 25134 Rye Canyon Loop Suite 300 Valencia, California | 91355 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (661) 775-5300
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On November 9, 2015, MannKind Corporation issued a press release announcing its financial results for the third quarter ended September 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished herewith:
99.1
Press Release of MannKind Corporation dated November 9, 2015, reporting MannKind's financial results for the third quarter ended September 30, 2015.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MannKind Corporation
(Registrant) |
||
| November 9, 2015
(Date) |
/s/ DAVID THOMSON, PH.D., J.D.
David Thomson, Ph.D., J.D. Corporate Vice President, General Counsel and Secretary |
EXHIBIT INDEX
|
Number |
Description |
|
99.1 |
Press Release of MannKind Corporation dated November 9, 2015, reporting MannKind's financial results for the third quarter ended September 30, 2015. |
EXHIBIT 99.1
MannKind Corporation Reports 2015 Third Quarter Financial Results
- Conference Call at 5:00 PM ET on November 9, 2015 -
VALENCIA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (TASE: MNKD) today reported financial results for the third quarter ended September 30, 2015.
For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product sales from our collaboration with Sanofi. For the quarter ended September 30, 2015, our portion of the loss sharing arrangement with Sanofi related to Afrezza was $14.7 million, which we subsequently financed by way of an advance under the loan facility with an affiliate of Sanofi after September 30, 2015. The amount currently outstanding under the Sanofi loan facility is now $43.7 million, which includes $0.8 million in paid-in-kind interest.
For the third quarter of 2015, total operating expenses decreased from $38.3 million to $26.0 million, a decline of 32.1%, compared to the same quarter in 2014, primarily due to Afrezza having moved out of clinical development into the commercial market. Additionally, non-cash stock compensation from the non-recurring achievement of performance and modification events in 2014 decreased in the third quarter of 2015 as compared to the third quarter of 2014. Research and development expenses decreased from $19.2 million to $6.3 million, a decrease of 67.2%, reflecting the transition from development to commercial activities. General and administrative expenses decreased from $19.1 million to $11.5 million, a reduction of 39.8%, mainly due to the decrease in non-cash stock compensation expense. Offsetting the total decrease of $20.5 million in R&D and G&A for the third quarter of 2015 were product manufacturing variance costs of $8.1 million. We did not recognize any product manufacturing costs in the third quarter of 2014 as we had not yet commenced commercialization of Afrezza.
For the first nine months of 2015, operating expenses were $71.8 million, a decline of 52.0% compared to the same period in 2014. Total research and development expenses for the nine months ended September 30, 2015 were $23.5 million, a decline of 71.6% compared to the same period in 2014, primarily due to reduced non-cash stock compensation expense resulting from the non-recurring achievement of performance and modification events in 2014 and in the first quarter of 2015. General and administrative expenses for the nine months ended September 30, 2015 were $32.6 million, a decrease of 51.2% compared to the same period in 2014, primarily due to reduced non-cash stock compensation expense resulting from the non-recurring achievement and modification events in 2014 and in the first quarter of 2015.
The net loss for the third quarter of 2015 was $31.9 million, or $0.08 per share, based on 405.2 million weighted average shares outstanding, compared with a net loss of $36.5 million, or $0.09 per share, based on 394.2 million weighted average shares outstanding for the third quarter of 2014. The number of common shares outstanding at September 30, 2015 was 418.3 million.
Cash and cash equivalents were $32.9 million at September 30, 2015, compared to $107.2 million in the second quarter of 2015. During the third quarter of 2015, we paid $64.3 million upon maturity of the 2015 notes and received $0.7 million in proceeds from warrant and option exercises, $7.2 million in payments from Sanofi for product shipments, and $12.2 million in net proceeds from our at-the-market sales facility. Currently, $30.1 million remains available to borrow under our amended loan arrangement with The Mann Group and $37.5 million of common stock remains available for sale under our at-the-market sales facility.
Conference Call
MannKind management will host a conference call to discuss these results today, November 9, 2015, at 5:00 p.m. Eastern Time. To participate in the call please dial (800) 708-4539 or (847) 619-6396 and use the participant passcode: 3859 3130. Those interested in listening to the conference call live via the Internet may do so by visiting MannKind's website at http://www.mannkindcorp.com.
A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 3859 3130#. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) (TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Forward-Looking Statements
Statements contained in this press release that are not strictly historical in nature are forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the extent to which MannKind's collaboration with Sanofi for commercialization of Afrezza is able to generate significant product sales for MannKind, difficulties or delays in obtaining regulatory feedback or completing and analyzing the results of clinical studies, MannKind's ability to manage its existing cash resources or raise additional capital, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
(Tables to follow)
| MannKind Corporation | ||||
| Condensed Consolidated Statements of Operations | ||||
| (Unaudited) | ||||
| (In thousands, except per share amounts) | ||||
|
Three months ended September 30, |
Nine months ended September 30, |
|||
| 2015 | 2014 | 2015 | 2014 | |
| Revenue | $ — | $ — | $ — | $ — |
| Operating expenses: | ||||
| Research and development | 6,341 | 19,178 | 23,455 | 82,684 |
| General and administrative | 11,547 | 19,088 | 32,649 | 66,840 |
| Product manufacturing | 8,115 | — | 15,688 | — |
| Total operating expenses | 26,003 | 38,266 | 71,792 | 149,524 |
| Loss from operations | (26,003) | (38,266) | (71,792) | (149,524) |
| Other income | 67 | 7,898 | 1,470 | 1,638 |
| Loss on extinguishment of debt | (1,049) | — | (1,049) | — |
| Interest expense on note payable to principal stockholder | (729) | (729) | (2,164) | (2,164) |
| Interest expense on notes | (4,145) | (5,424) | (17,899) | (11,895) |
| Interest income | 2 | 1 | 8 | 4 |
| Net loss | $ (31,857) | $ (36,520) | $ (91,426) | $ (161,941) |
| Net loss per share — basic and diluted | $ (0.08) | $ (0.09) | $ (0.23) | $ (0.42) |
| Shares used to compute basic and diluted net loss per share | 405,199 | 394,163 | 401,734 | 381,332 |
| MannKind Corporation | ||
| Condensed Consolidated Balance Sheet | ||
| (Unaudited) | ||
| (in thousands) | ||
| September 30, 2015 | December 31, 2014 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 32,928 | $ 120,841 |
| Receivables from collaboration | 1,679 | 50,436 |
| Inventory | 23,402 | 9,670 |
| Prepaid expenses and other current assets | 13,227 | 20,206 |
| Total current assets | 71,236 | 201,153 |
| Property and equipment — net | 191,408 | 192,127 |
| Deferred product costs from collaboration | 13,539 | — |
| Other assets | 1,831 | 1,159 |
| Total | $ 278,014 | $ 394,439 |
| Liabilities and Stockholders' Deficit | ||
| Accounts payable | $ 4,444 | $ 7,394 |
| Accrued expenses and other current liabilities | 14,081 | 26,206 |
| Facility financing obligation | 74,163 | 72,995 |
| Senior convertible notes | — | 99,355 |
| Deferred product sales from collaboration | 17,474 | 436 |
| Deferred payments from collaboration | 157,145 | 196,967 |
| Current liabilities | 267,307 | 403,353 |
| Note payable to related party | 49,521 | 49,521 |
| Sanofi loan facility and loss share obligation | 43,653 | 3,034 |
| Senior convertible notes | 27,607 | — |
| Other liabilities | 14,495 | 12,301 |
| Stockholders' deficit | (124,569) | (73,770) |
| Total | $ 278,014 | $ 394,439 |
PLACEHOLDER
CONTACT: Company Contact:
Matthew J. Pfeffer
Chief Financial Officer
661-775-5300
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
- Greenlane Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
- AERWINS Technologies Announces Additional Staff Determination
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
